217 related articles for article (PubMed ID: 16802006)
21. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
22. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
Pawłowska M; Palewicz E; Halota W
Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742
[TBL] [Abstract][Full Text] [Related]
23. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
Jessner W; Stauber R; Hackl F; Datz C; Watkins-Riedel T; Hofer H; Gangl A; Kessler H; Ferenci P
J Viral Hepat; 2003 Jan; 10(1):37-42. PubMed ID: 12558910
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
[TBL] [Abstract][Full Text] [Related]
25. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
27. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
[TBL] [Abstract][Full Text] [Related]
28. Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin.
Marino N; Blanc PL; Blè C; Pierotti P; Mazzotta F
J Biol Regul Homeost Agents; 2003; 17(2):205-6. PubMed ID: 14518725
[TBL] [Abstract][Full Text] [Related]
29. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis.
Coppola N; Pisaturo M; Tonziello G; Sagnelli C; Sagnelli E; Angelillo IF
BMC Infect Dis; 2012 Dec; 12():357. PubMed ID: 23245594
[TBL] [Abstract][Full Text] [Related]
31. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
32. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
34. Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.
Horsmans Y; Colle I; Van Vlierberghe H; Langlet P; Adler M; Bourgeois N; Brenard R; Michielsen P; Goossens A; Bruckers L;
Acta Gastroenterol Belg; 2008; 71(3):293-7. PubMed ID: 19198574
[TBL] [Abstract][Full Text] [Related]
35. Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.
Toyoda H; Kumada T
Expert Opin Pharmacother; 2009 Dec; 10(17):2845-57. PubMed ID: 19891593
[TBL] [Abstract][Full Text] [Related]
36. [Hepatitis C--treatment of untreated (naive) patients].
Duvnjak M; Pavić T; Tomasić V; Lerotić I; Virović L
Acta Med Croatica; 2005; 59(5):453-61. PubMed ID: 16381243
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
38. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
39. [The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy].
Husa P; Slesinger P; Stroblová H; Svobodník A
Vnitr Lek; 2006 Jun; 52(6):590-5. PubMed ID: 16871762
[TBL] [Abstract][Full Text] [Related]
40. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]